Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease

Kong-Xiang Zhu1,2, Pei-Yuan Song1,2, He-Li1,2

  • 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.

Insights

The FMO3 rs1736557 AA genotype increases clopidogrel

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for coronary artery disease (CAD) patients post-percutaneous coronary intervention.
  • High on-treatment platelet reactivity (HTPR) during clopidogrel therapy increases risks of stent thrombosis and ischemic events.
  • CYP2C19 loss-of-function variants are known to cause HTPR; FMO3's role in platelet responsiveness is also noted.

Purpose of the Study:

  • To investigate the association between the FMO3 rs1736557 polymorphism and clopidogrel response in Chinese CAD patients.
  • To determine if FMO3 rs1736557 influences clopidogrel's antiplatelet potency.

Main Methods:

  • 522 Chinese CAD patients receiving DAPT were studied.
  • Platelet reactivity was measured using the vasodilator-stimulated phosphoprotein-phosphorylation assay after clopidogrel administration (loading or maintenance dose).
  • FMO3 rs1736557 and CYP2C19 polymorphisms (*2, *3) were genotyped using PCR-RFLP.

Main Results:

  • CYP2C19 poor and intermediate metabolizers exhibited significantly higher platelet reactivity than extensive metabolizers.
  • FMO3 rs1736557 AA homozygotes showed significantly lower platelet reactivity compared to carriers of the G allele.
  • The FMO3 rs1736557 A allele was associated with a significantly decreased risk of HTPR, particularly in patients with CYP2C19 loss-of-function alleles on maintenance dose therapy.

Conclusions:

  • The FMO3 rs1736557 AA genotype is linked to enhanced antiplatelet potency of clopidogrel in Chinese CAD patients.
  • This finding suggests FMO3 rs1736557 may be a genetic marker influencing clopidogrel efficacy.
  • Further research is needed to validate these pharmacogenomic findings.
Abstract

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.6K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
116
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.7K
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
205
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
146